Affimed to Showcase Innovative Cancer Treatments
Affimed N.V. (Nasdaq: AFMD), a forward-thinking company at the forefront of immuno-oncology, is set to make a significant presence at the upcoming Leerink Partners Global Healthcare Conference. This event offers a platform for industry leaders to discuss advancements in healthcare and biotechnology.
A Key Note by the CEO
During the conference, the spotlight will be on Affimed’s Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh. He will be partaking in an engaging fireside chat where he will discuss Affimed's cutting-edge technology and strategies aimed at empowering patients in their battle against cancer.
Understanding Affimed’s Role in Cancer Therapy
Affimed is dedicated to reshaping cancer treatment through its innovative approach to immuno-oncology. By harnessing the untapped capabilities of the innate immune system, the company aims to create therapies that not only target tumors effectively but also resonate with the body’s natural defenses. The company's innate cell engagers (ICE) are crucial to this mission, enabling targeted recognition and eradication of a variety of tumors.
A Deep Dive into the ICE Platform
The proprietary ROCK platform developed by Affimed plays a pivotal role in creating these personalized ICE solutions. This innovative technology consistently generates tailored molecules designed to engage innate immune cells, facilitating the destruction of tumor cells. As the clinical landscape evolves, Affimed's ICE molecules are currently undergoing rigorous clinical studies as both standalone and combination therapies.
The Future of Cancer Treatment
With a strong commitment to innovation and patient care, Affimed is on a journey to transform how cancer therapies are viewed and administered. The company's experienced team of experts drives this mission forward, fueled by a shared vision to prevent cancer from interrupting the lives of patients.
Engagement Beyond the Conference
For those interested in learning more about Affimed's initiatives, a live webcast of Dr. Leland's presentation will be accessible via the company's official website. Attendees and interested parties can also look forward to a replay available for about a month following the event. This accessibility underscores Affimed's commitment to transparency and engagement with stakeholders.
Connecting with Affimed
Those wishing to delve deeper into Affimed’s management, product pipeline, and potential collaborations are encouraged to connect with the company during the conference. Meetings can be arranged through Leerink Partners representatives or directly through Affimed’s investor relations contact.
Contact Information
For inquiries regarding Affimed's participation, the designated investor relations contact is Alexander Fudukidis, Director and Head of Investor Relations. He is readily available via email or phone for more detailed discussions related to investor interests.
Frequently Asked Questions
What is Affimed N.V. known for?
Affimed is recognized for its innovative approach to immuno-oncology, focusing on enhancing the innate immune response to treat cancer.
Who will represent Affimed at the conference?
Dr. Shawn Leland, the CEO of Affimed, will be representing the company and sharing insights during a fireside chat.
Where can I access the live presentation?
A live webcast of the conference presentation will be available on Affimed’s official website.
How does Affimed's technology work?
Affimed's technology harnesses the innate immune system through innate cell engagers (ICE) that target and kill cancer cells effectively.
How can investors get in touch with Affimed?
Investors can reach out to Alexander Fudukidis for any investment-related questions or to schedule meetings at the conference.
